Education
About Us
Working with TipRanks
Follow Us
Captor Therapeutics SA (DE:60Q)
STUTTGART:60Q
Total Valuation
Captor Therapeutics SA has a market cap or net worth of €49.72M. The enterprise value is €137.39M.
Market Cap€49.72M
Enterprise Value€137.39M
Share Statistics
Captor Therapeutics SA has 5,528,709 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,528,709
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Captor Therapeutics SA’s return on equity (ROE) is -0.60 and return on invested capital (ROIC) is -63.75%.
Return on Equity (ROE)-0.60
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-63.75%
Return on Capital Employed (ROCE)-0.66
Revenue Per Employee150.71K
Profits Per Employee-365.96K
Employee Count105
Asset Turnover0.18
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Captor Therapeutics SA is ―. Captor Therapeutics SA’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value3.06
Price to FCF0.00
Price to Operating Cash Flow170.51
PEG Ratio―
Income Statement
In the last 12 months, Captor Therapeutics SA had revenue of 15.82M and earned -38.43M in profits. Earnings per share was -8.25.
Revenue15.82M
Gross Profit6.42M
Operating Income-44.76M
Pretax Income-38.43M
Net Income-38.43M
EBITDA-32.93M
Earnings Per Share (EPS)-8.25
Cash Flow
In the last 12 months, operating cash flow was 1.26M and capital expenditures -507.00K, giving a free cash flow of -4.02M billion.
Operating Cash Flow1.26M
Free Cash Flow-4.02M
Free Cash Flow per Share-0.73
Dividends & Yields
Captor Therapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.18
52-Week Price Change-44.22%
50-Day Moving Average8.81
200-Day Moving Average8.95
Relative Strength Index (RSI)51.60
Average Volume (3m)0.00
Important Dates
Captor Therapeutics SA upcoming earnings date is Nov 20, 2025, TBA (Confirmed).
Last Earnings DateSep 11, 2025
Next Earnings DateNov 20, 2025
Ex-Dividend Date―
Financial Position
Captor Therapeutics SA as a current ratio of 3.90, with Debt / Equity ratio of 8.66%
Current Ratio3.90
Quick Ratio3.90
Debt to Market Cap0.01
Net Debt to EBITDA1.02
Interest Coverage Ratio-102.43
Taxes
In the past 12 months, Captor Therapeutics SA has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Captor Therapeutics SA EV to EBITDA ratio is -4.96, with an EV/FCF ratio of -5.10.
EV to Sales10.33
EV to EBITDA-4.96
EV to Free Cash Flow-5.10
EV to Operating Cash Flow-5.17
Balance Sheet
Captor Therapeutics SA has €61.42M in cash and marketable securities with €4.69M in debt, giving a net cash position of €56.73M billion.
Cash & Marketable Securities€61.42M
Total Debt€4.69M
Net Cash€56.73M
Net Cash Per Share€10.26
Tangible Book Value Per Share€13.75
Margins
Gross margin is 60.15%, with operating margin of -282.84%, and net profit margin of -242.82%.
Gross Margin60.15%
Operating Margin-282.84%
Pretax Margin-242.82%
Net Profit Margin-242.82%
EBITDA Margin-208.09%
EBIT Margin-240.06%
Analyst Forecast
The average price target for Captor Therapeutics SA is €8.67, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target€8.67
Price Target Upside-6.37% Downside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―